Collegium Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
Collegium Pharmaceutical has a total shareholder equity of $234.3M and total debt of $986.0M, which brings its debt-to-equity ratio to 420.9%. Its total assets and total liabilities are $1.6B and $1.4B respectively. Collegium Pharmaceutical's EBIT is $217.7M making its interest coverage ratio 4. It has cash and short-term investments of $120.0M.
Key information
420.9%
Debt to equity ratio
US$986.02m
Debt
| Interest coverage ratio | 4x |
| Cash | US$119.96m |
| Equity | US$234.28m |
| Total liabilities | US$1.40b |
| Total assets | US$1.64b |
Recent financial health updates
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Recent updates
Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet
Dec 24Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Nov 26Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality
Nov 14Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Oct 28Collegium Pharmaceutical: Diversifying And Growing
Aug 09Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking
Jul 24Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Jun 05Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Financial Position Analysis
Short Term Liabilities: COLL's short term assets ($443.8M) do not cover its short term liabilities ($459.4M).
Long Term Liabilities: COLL's short term assets ($443.8M) do not cover its long term liabilities ($941.4M).
Debt to Equity History and Analysis
Debt Level: COLL's net debt to equity ratio (369.7%) is considered high.
Reducing Debt: COLL's debt to equity ratio has increased from 13.6% to 420.9% over the past 5 years.
Debt Coverage: COLL's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: COLL's interest payments on its debt are well covered by EBIT (4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 14:47 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Collegium Pharmaceutical, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Dana Flanders | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |